Bookmark and Share
BioAssay: AID 624301

Late stage assay provider counterscreen for inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1): absorbance-based cell-based dose response assay for inhibitors of DAX-1 (CAT activity)

Name: Late stage assay provider counterscreen for inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1): absorbance-based cell-based dose response assay for inhibitors of DAX-1 (CAT activity). ..more
_
   
 Tested Compounds
 Tested Compounds
All(2)
 
 
Inactive(2)
 
 
 Tested Substances
 Tested Substances
All(2)
 
 
Inactive(2)
 
 
AID: 624301
Data Source: The Scripps Research Institute Molecular Screening Center (DAX1-CAT_INH_ABS_0096_3XIC50 MDCSRUN (run by assay provider))
BioAssay Type: Panel
Depositor Category: NIH Molecular Libraries Probe Production Network, Assay Provider
Deposit Date: 2012-06-19
Hold-until Date: 2013-06-18
Modify Date: 2013-06-18

Data Table ( Complete ):           View All Data
Tested Compounds:
Related Experiments
Show more
AIDNameTypeComment
504766Luminescence-based primary cell-based high throughput screening assay to identify inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1)Screeningdepositor-specified cross reference: Primary screen (DAX1 inhibitors in singlicate)
504790Summary of the probe development efforts to identify inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1)Summarydepositor-specified cross reference: Summary (DAX1 inhibitors)
588797Luminescence-based cell-based high throughput dose response assay for inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1)Confirmatorydepositor-specified cross reference: Dose Response (DAX1 inhibitors in triplicate)
588799Counterscreen for inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1): luminescence-based cell-based high throughput dose response assay to identify compounds that interfere with the UAS/Gal4 system and/or luciferase reporterConfirmatorydepositor-specified cross reference: Dose response counterscreen (GAL4 inhibitors in triplicate)
588821Late stage counterscreen for inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1): luminescence-based cell-based dose response assay to identify compounds that interfere with the UAS/Gal4 system and/or luciferase reporter.Screeningdepositor-specified cross reference: Dose response counterscreen (GAL4 inhibitors in triplicate)
588822Late stage luminescence-based cell-based dose response assay for inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1).Screeningdepositor-specified cross reference: Dose Response (DAX1 inhibitors in triplicate)
624302Late stage assay provider luminescence-based cell-based dose response assay for inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1)Othersame project related to Summary assay
624307Late stage assay provider counterscreen for inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1): luminescence-based cell-based dose response assay for inhibitors of Star (Steroidogenic acute regulatory protein)Othersame project related to Summary assay
624313Late stage counterscreen for inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1): absorbance-based cell-based assay to identify inhibitors of the DAX-1 target gene, cytochrome P450, family 11, subfamily A, polypeptide 1 (CYP11A1)Screeningsame project related to Summary assay
624314Late stage counterscreen for inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1): absorbance-based cell-based assay to identify inhibitors of the DAX-1 target gene, 3B-HSD (3 beta-hydroxysteroid dehydrogenase)Othersame project related to Summary assay
Description:
Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRIMSC)
Affiliation: The Scripps Research Institute, TSRI
Assay Provider: Enzo Lalli, CNRS
Network: Molecular Library Probe Production Centers Network (MLPCN)
Grant Proposal Number: R03 DA030558-01
Grant Proposal PI: Enzo Lalli, CNRS
External Assay ID: DAX1-CAT_INH_ABS_0096_3XIC50 MDCSRUN (run by assay provider)

Name: Late stage assay provider counterscreen for inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1): absorbance-based cell-based dose response assay for inhibitors of DAX-1 (CAT activity).

Description:

Nuclear receptors are a family of small molecule and hormone-regulated transcription factors that share conserved DNA-binding (DBD) and ligand-binding domains (LBD). Small pharmacological compounds able to bind to the cleft of the ligand-binding domain could alter its conformation and subsequently modify transcription of target genes. Such ligand agonists and/or antagonists have already been successfully designed for 23 nuclear receptors among the 48 previously identified in the human genome (1-3). Of interest, DAX-1 (NR0B1; dosage-sensitive sex reversal-adrenal hypoplasia congenita critical region on the X chromosome gene 1) has been shown to act as a robust transcriptional repressor, inhibiting genes involved in steroidogenesis through interaction with corepressors and regulating the pluripotency of stem cells (4-8). The human DAX-1 gene encodes a protein whose C terminus is similar to the LBD of nuclear hormone receptors, while its N terminus is composed of three cysteine-rich 70 amino acids with little similarity to known proteins (4, 7). Mutations in Dax-1 have been shown to cause the X-linked form of adrenal hypoplasia congenita (AHC), associated with hypogonadotropic hypogonadism (HHG). AHC-HHG-associated mutations share an altered DAX-1 C-terminal domain (5, 9), resulting in loss of transcriptional repression activity (5, 7, 9). This finding suggests that the impairment of the DAX-1 transcriptional activity is directly linked to the pathogenesis of AHC-HHG. In addition, Dax-1 has also been shown to be highly expressed in pediatric Ewing tumors (10). As a result, the identification of selective inhibitors of Dax-1 will serve as useful tools to elucidate the developmental and tumorigenic roles of Dax-1, and its maintenance of stem cell pluripotency.

References:

1, Evans RM. The nuclear receptor superfamily: a rosetta stone for physiology. Mol Endocrinol 19:1429-1438, 2005.
2. Kliewer SA, Lehmann JM, and Willson TM. Orphan nuclear receptors: shifting endocrinology into reverse. Science 284: 757-760, 1999.
3. Li Y, Lambert MH, and Xu HE. Activation of nuclear receptors: a perspective from structural genomics. Structure (Camb) 11: 741-746., 2003.
4. Lalli, E., M. H. Melner, D. M. Stocco, and P. Sassone-Corsi. 1998. DAX-1 blocks steroid production at multiple levels. Endocrinology 139:4237-4243. 22. Lalli, E., and P. Sassone-Corsi. 1999. DAX-1 and the adrenal cortex. Curr. Opin. Endocrinol. Diabetes 6:185-190.
5. Ito, M., R. Yu, and J. L. Jameson. 1997. DAX-1 inhibits SF-1-mediated transactivation via a carboxy-terminal domain that is deleted in adrenal hypoplasia congenita. Mol. Cell. Biol. 17:1476-1483.
6. Zazopoulos, E., E. Lalli, D. M. Stocco, and P. Sassone-Corsi. 1997. DNA binding and transcriptional repression by DAX-1 blocks steroidogenesis. Nature 390:311-315.
7. Lalli, E., B. Bardoni, E. Zazopoulos, J.-M. Wurtz, T. M. Strom, D. Moras, and P. Sassone-Corsi. 1997. A transcriptional silencing domain in DAX-1 whose mutation causes adrenal hypoplasia congenita. Mol. Endocrinol. 11:1950-1960.
8. Lalli E, Alonso J. Targeting DAX-1 in embryonic stem cells and cancer. Expert Opin Ther Targets. 2010 Feb;14(2):169-77.
9. Zanaria, E., F. Muscatelli, B. Bardoni, T. M. Strom, S. Guioli, W. Guo, E. Lalli, C. Moser, A. P. Walker, E. R. B. McCabe, T. Meitinger, A. P. Monaco, P. Sassone-Corsi, and G. Camerino. 1994. An unusual member of the nuclear hormone receptor superfamily responsible for X-linked adrenal hypoplasia congenita. Nature 372:635-641.
10. Mendiola M, Carrillo J, Garcia E, Lalli E, Hernandez T, de Alava E, Tirode F, Delattre O, Garcia-Miguel P, Lopez-Barea F, Pestana A, Alonso J. The orphan nuclear receptor DAX1 is up-regulated by the EWS/FLI1 oncoprotein and is highly expressed in Ewing tumors. Int J Cancer. 2006 Mar 15;118(6):1381-9.

Keywords:

late stage, assay provider, Chloramphenicol acetyltransferase, CAT, reporter, powders, SAR, purchased, synthesized, medchem, DAX-1, Dax, Dax1, NR0B1, dosage-sensitive sex reversal, adrenal hypoplasia critical region, on chromosome X, gene 1, dose response, dose, titration, orphan, nuclear, nuclear receptor, NR, X chromosome, Gal4, reporter, inhibit, inhibitor, repressor, antagonist, adrenal, gonad, steroidogenic, hormone, AHC, stem cell, Ewing, tumor, cancer, triplicate, Scripps Florida, The Scripps Research Institute Molecular Screening Center, SRIMSC, Molecular Libraries Probe Production Centers Network, MLPCN.
Panel Information
Assays
PID§NameSubstancePanel TargetsDescriptionAdditional Information
ActiveInactive
1CAT2
2CAT + DAX12nuclear receptor subfamily 0 group B member 1 [Homo sapiens] [gi:5016090]
Taxonomy id: 9606
Gene id: 190

§ Panel component ID.
Protocol
Assay Overview:

The purpose of this assay is to confirm whether powder samples of compounds identified as Dax-1 inhibitor probe candidates can inhibit Dax-1, as measured by activation of promoter activity of Chloramphenicol acetyltransferase (CAT). CAT is an enzyme encoded by a bacterial drug-resistance gene which inactivates chloramphenicol by acetylating the drug at one or both of its two hydroxyl groups. Since this gene is not found in eukaryotes, eukaryotic cells express no background CAT activity.

This orthogonal assay employs HEK293 cells co-transfected with a GAL4 DBD-DAX1 C-terminal construct (pG4D 207-470) and a CAT reporter under control of the thymidine kinase promoter preceded by yeast Gal4 binding sites (pGAL4-tk-CAT). In this assay, transfected cells are incubated with test compounds, followed by cell lysis and assay of CAT enzymatic activity, which is proportional to promoter activity, by a colorimetric assay. DAX1 represses expression of the CAT reporter plasmid. As designed, a DAX1 inhibitor will prevent or reduce DAX-1-mediated transcriptional repression, leading to increased expression of the CAT reporter gene, and increased well absorbance. Compounds are tested in triplicate using a 4-point, 1:2 dilution series, starting at a nominal test concentration of 100 uM.

Protocol Summary:

HEK293 cells were routinely cultured in T-75 flasks containing 15 mL of DMEM (4.5 g/L glucose) medium supplemented with 10% v/v fetal bovine serum and 1% v/v penicillin-streptomycin at 37 C, 5% CO2 and 95% relative humidity (RH). When cells reached about 70% confluency, they were transfected with 1.5 mL of serum-free OptiMEM containing 7.8 ug of the pGal4-tk-CAT reporter plasmid, 7.8 ug of the Gal4 DBD-DAX1 fusion expression vector pG4D 207-470, and 31.25 uL of TransIT-293 transfection reagent. In the absence of a pharmacological positive control, DAX-1 inhibition was mimicked by transfecting cells with the empty vector pG4M polyII instead of the pG4D 207-470 vector. Four hours post transfection, cells were harvested using 3 mL of trypsin-EDTA solution and resuspended at a concentration of 400,000 cells per mL in the wells of 12-well plates (0.5 mL per well), diluted in DMEM supplemented as above. Transfected cells were then incubated at 37 C, 5% CO2 and 95% RH for 16 hours before CAT assay. 0.5 mL of each dilution of the test compounds or DMSO control to reach the appropriate final concentration were also added to the wells. Transfection experiments were performed in duplicate and repeated three times for each tested drug concentration.

CAT activity in transfected HEK293 cells was assayed using a colorimetric EIA assay, following the manufacturer's instructions. The relative CAT activity of each test compound was calculated as follows:

Relative_Activity = (average absorbance of test compound wells) / (average absorbance of DMSO wells)

PubChem Activity Outcome and Score:

For the CAT alone wells, compounds with a relative activity less than 1.25 at all doses were considered inactive. Compounds with a relative activity equal to or greater than 1.25 at any concentration were considered active.

For the CAT + DAX1 wells, compounds with a relative activity less than 1.25 at all doses were considered inactive. Compounds with a relative activity equal to or greater than 1.25 at any concentration were considered active.

Overall Outcome and Score:

For the CAT + DAX1 wells, any compound that increased activity above 5 or reduced activity below 0.1 at any dose were considered active. Compounds that did not increase activity above 5-fold or reduced activity below 0.1 at all doses were considered inactive.

The PubChem Activity Score range for inactive compounds is 0-0. There are no active compounds.

List of Reagents:

pGAL4-tk-CAT reporter plasmid (supplied by Assay Provider)
pG4D 207-470 DAX-1 expression plasmid (supplied by Assay Provider)
pG4M polyII empty plasmid (supplied by Assay Provider)
HEK293 cells (ATCC, part CRL-1573)
DMEM (Invitrogen, part 11965)
FBS (Invitrogen, part 10106-169)
Penicillin-Streptomycin 100X Liquid Solution (Invitrogen, part 15140-130)
TransIT 293 (Mirus Corporation, part MIR-2700)
OptiMEM (Invitrogen, part 31985)
Trypsin-EDTA solution (Invitrogen, part 25300-104)
CAT ELISA (Roche, part 113637270001)
White, clear bottom 96-well plates (Corning, part 3903)
Comment
This assay was performed by the assay provider's lab. This assay may have been run as two or more separate campaigns, each campaign testing a unique set of compounds. All data reported were normalized on a per-plate basis. Possible artifacts of this assay can include, but are not limited to: dust or lint located in or on wells of the microtiter plate, and compounds that modulate well absorbance. All test compound concentrations reported above and below are nominal; the specific test concentration(s) for a particular compound may vary based upon the actual sample provided.
Result Definitions
Show more
TIDNameDescriptionPID§Panel TargetsHistogramTypeUnit
OutcomeThe BioAssay activity outcomeOutcome
1Outcome [CAT]The BioAssay activity outcome.1Outcome
2Relative Activity at 12.5 uM [CAT] (12.5μM**)The normalized value of absorbance at a test compound concentration of 12.5 micromolar1Floatratio
3Relative Activity at 25 uM [CAT] (25μM**)The normalized value of absorbance at a test compound concentration of 25 micromolar1Floatratio
4Relative Activity at 50 uM [CAT] (50μM**)The normalized value of absorbance at a test compound concentration of 50 micromolar1Floatratio
5Relative Activity at 100 uM [CAT] (100μM**)The normalized value of absorbance at a test compound concentration of 100 micromolar1Floatratio
6Outcome [CAT + DAX1]The BioAssay activity outcome.2nuclear receptor subfamily 0 group B member 1 [Homo sapiens]Outcome
7Relative Activity at 12.5 uM [CAT + DAX1] (12.5μM**)The normalized value of absorbance at a test compound concentration of 12.5 micromolar2Floatratio
8Relative Activity at 25 uM [CAT + DAX1] (25μM**)The normalized value of absorbance at a test compound concentration of 25 micromolar2Floatratio
9Relative Activity at 50 uM [CAT + DAX1] (50μM**)The normalized value of absorbance at a test compound concentration of 50 micromolar2Floatratio
10Relative Activity at 100 uM [CAT + DAX1] (100μM**)The normalized value of absorbance at a test compound concentration of 100 micromolar2Floatratio

** Test Concentration. § Panel component ID.
Additional Information
Grant Number: R03 DA030558-01

Classification
PageFrom: